Homocysteine Longevity-Medicine Target Ranges: What Optimal Looks Like
At a glance
- Homocysteine, what it is / a sulfur-containing amino acid produced during methionine metabolism, measured on fasting plasma
- Conventional lab "normal" ceiling / roughly 15 µmol/L on most reference ranges
- Longevity-medicine working target / roughly 7 to 10 µmol/L (clinical convention, not a guideline-endorsed cutoff)
- Guideline status / no major U.S. cardiology guideline sets a treatment target or recommends universal screening
- Outcome-trial status / B-vitamin therapy reliably lowers homocysteine but has not shown reduced cardiovascular events in trials of people with existing disease
- Common correctable drivers / low folate, low B12, low B6, kidney impairment, hypothyroidism, some medications
- Genetic factor / MTHFR C677T variant reduces conversion of folate to its active form, more so in TT homozygotes
- Retest timing / roughly 8 to 12 weeks after starting or changing supplementation
Is "normal" the same as optimal here?
No, and that gap is the whole reason this page exists. A homocysteine reference range calibrated to catch frank hyperhomocysteinemia is not the same thing as a range calibrated to minimize long-term vascular or cognitive risk. Homocysteine sits at the intersection of three nutrient-dependent pathways: remethylation back to methionine (needs folate and B12), transsulfuration to cystathionine (needs B6), and direct release into plasma, where sustained elevation is associated with endothelial injury. Because those pathways depend on nutrients that are commonly under-consumed, plasma homocysteine works reasonably well as an inexpensive proxy for B-vitamin adequacy and methylation status.
Standard reference ranges (commonly extending up to roughly 15 µmol/L) were set to flag overt deficiency states and homocystinuria-range elevations, not to define a low-risk zone. Multiple prospective cohort studies have reported that cardiovascular and all-cause mortality risk begins rising at concentrations well below that lab ceiling, with no clear threshold effect. This is the observational basis for the longevity-medicine convention of treating toward roughly 7 to 10 µmol/L rather than simply staying "in range."
The strongest, most defensible statement the current evidence supports is this: standard lab reference ranges for homocysteine are built to catch disease, not to define low-risk status, and cohort studies consistently show rising cardiovascular and mortality risk starting well below the typical lab ceiling of about 15 µmol/L. A commonly used longevity-medicine target of 7 to 10 µmol/L reflects that observational risk gradient. It is not a value validated in a randomized outcome trial, and large trials that lowered homocysteine with B vitamins in people with established cardiovascular disease did not reduce cardiovascular events.
Where does the 7 to 10 µmol/L target come from, and how solid is it?
The number is not arbitrary, but it is also not a regulatory or guideline threshold. It is built from converging signals across several types of evidence, each with a different level of certainty.
Cohort studies (observational, hypothesis-generating). Large population studies following adults for years have reported that both cardiovascular mortality and all-cause mortality track upward as homocysteine rises, with the association visible starting somewhere in the high single digits to low teens (µmol/L), well inside what most labs still call "normal." Older prospective cohorts have also linked higher homocysteine to greater risk of dementia and Alzheimer's disease compared with lower concentrations in the same population. These associations are consistent across multiple independent cohorts, which is meaningful, but observational data cannot prove that homocysteine itself causes the excess risk rather than marking some other process, such as poor overall nutrition, kidney function decline, or aging.
Trials that lower homocysteine (higher-quality evidence, mixed result). Randomized trials and systematic reviews confirm that B-vitamin supplementation reliably lowers homocysteine, often substantially. Where the evidence gets more complicated is on hard outcomes: large secondary-prevention trials that lowered homocysteine with folic acid and B vitamins in people who already had cardiovascular disease (including trials commonly cited in this literature as NORVIT and HOPE-2) did not show a reduction in heart attacks, strokes, or cardiovascular death, despite successfully lowering the biomarker. One trial in older adults with mild cognitive impairment and elevated baseline homocysteine reported slower brain atrophy on MRI with high-dose B-vitamin therapy, a more mechanistic, imaging-based endpoint rather than a hard clinical outcome.
The honest interpretation. The epidemiological signal (higher homocysteine tracks with worse outcomes) and the trial signal (lowering homocysteine in people with existing disease does not clearly improve hard outcomes) are both real and both need to be held at once. A plausible explanation is that these outcome trials enrolled people with cardiovascular disease already established, past the point where correcting a biomarker could meaningfully change the disease trajectory. Longevity medicine's bet is that intervening earlier, in asymptomatic people decades before disease is established, could behave differently. That bet is biologically reasonable but has not been tested in a large primary-prevention outcome trial, and readers should not treat a homocysteine target of 7 to 10 as though it carries the same evidentiary weight as, for example, an LDL cholesterol target from a statin outcome trial.
What is established, what is plausible, and what is not established
Established: Homocysteine reflects folate, B12, and B6 status and rises with kidney impairment. B-vitamin supplementation lowers plasma homocysteine reliably and substantially. The MTHFR C677T variant reduces enzymatic conversion of folate to its active form, more markedly in people homozygous for the variant. Elevated homocysteine is statistically associated with cardiovascular disease, dementia, and mortality across multiple cohort studies.
Plausible but unproven: That deliberately treating homocysteine down to a specific number such as 7 to 10 µmol/L in an otherwise healthy person reduces future cardiovascular events, dementia, or death. That earlier intervention (before disease is established) would succeed where secondary-prevention trials failed.
Not established: Any universal "optimal" homocysteine number endorsed by a cardiology or laboratory guideline body. A specific numeric floor below which lower is confirmed to be better; some cohort data raise questions about very low values without settling the matter.
How homocysteine is tested
Plasma homocysteine is drawn fasting, generally after at least 8 hours without food, because a recent high-protein meal can transiently raise the result. Both chemiluminescent immunoassay and HPLC methods are used clinically; HPLC is considered the more precise reference method, but immunoassay is adequate for routine monitoring. Because the result integrates B-vitamin status over recent weeks rather than the prior day, it behaves somewhat like HbA1c: useful for tracking a trend, not for same-day decisions. Retesting sooner than about 8 weeks after starting or changing supplementation does not give a reliable picture of the treatment effect.
A working interpretation table (clinical convention, not a lab-validated cutoff)
| Tier | Approximate range | How to read it |
|---|---|---|
| Longevity-medicine target | 7 to 10 µmol/L | Associated with the lower end of cohort risk gradients; a common clinical goal, not a guideline threshold |
| Borderline / "normal" on most labs | 10 to 15 µmol/L | Will not be flagged on a standard panel, but sits above the longevity target; correctable causes are common here |
| Hyperhomocysteinemia | roughly 15 to 30 µmol/L | Generally warrants evaluation for B-vitamin deficiency, renal function, and thyroid status |
| Markedly elevated | above roughly 30 µmol/L, and especially very high values | Warrants a more formal workup; very high results can reflect homocystinuria or significant renal or metabolic disease and should not be managed with a self-directed supplement trial |
What raises homocysteine, and which causes are fixable
Diet and micronutrient status. Insufficient dietary folate is probably the most common correctable driver in otherwise healthy adults; population surveys have found a meaningful share of U.S. Adults fall short of recommended folate intake. B12 deficiency, more common with age due to declining gastric acid and intrinsic factor, and B6 insufficiency both raise homocysteine through different pathways.
MTHFR C677T genotype. This common variant reduces the enzyme's efficiency, more so in people homozygous for it (roughly 10 to 15% of people of European ancestry, according to widely cited genetics literature). People with this genotype convert standard folic acid to its active form less efficiently and often respond better to pre-formed 5-methyltetrahydrofolate (5-MTHF, methylfolate) than to folic acid. Genotype status should generally be discussed with a clinician rather than assumed from ancestry alone.
Kidney function. The kidneys clear homocysteine, so reduced glomerular filtration rate reliably raises plasma levels. In people with chronic kidney disease, B-vitamin supplementation still lowers homocysteine, but the response is smaller and the downstream cardiovascular benefit remains unproven, consistent with the trial data described above.
Thyroid status and medications. Elevated TSH can impair B12 metabolism and raise homocysteine. Long-term metformin use is a recognized cause of B12 deficiency and is worth checking in anyone on it for several years. Proton pump inhibitors can similarly reduce B12 absorption over time. Testosterone replacement therapy and other anabolic androgen use may modestly raise homocysteine through increased methionine turnover; this is a plausible mechanism rather than a well quantified effect, and periodic monitoring is a reasonable precaution rather than a proven necessity.
Should you supplement, and with what?
Folate and B12 supplementation are the best-supported way to lower homocysteine, and B6 mainly addresses a different pattern (the post-methionine-load response) rather than fasting homocysteine itself. Typical approaches described in the trial literature and used in longevity-medicine practice include methylfolate in the range of roughly 400 to 1,000 mcg per day and methylcobalamin in the range of roughly 500 to 1,000 mcg per day, with B6 added when a post-load pattern is a specific concern. These are examples of commonly used ranges from published research and clinical practice, not an individualized prescription; actual dosing should be set by a clinician based on baseline labs, kidney function, and other medications.
Before adding supplements, it is worth checking the variables that can blunt or confound the response: TSH, serum B12 (paired with methylmalonic acid if B12 is borderline), estimated GFR, and a basic metabolic panel. Supplementing without checking these can produce a repeat homocysteine test that has not moved, for reasons that had nothing to do with the vitamin dose.
Dietary sources rich in folate (dark leafy greens, legumes, liver, fortified grains) and B12 (fish, shellfish, liver, dairy, eggs) can meaningfully lower homocysteine in people whose baseline intake has been poor, though supplementation tends to work faster and more predictably when a documented deficiency is present.
What cardiology guidelines actually say, and why there is tension
No major U.S. Cardiology guideline currently recommends universal homocysteine screening or specifies a treatment target. Guideline language in this space has generally acknowledged the epidemiological association between elevated homocysteine and cardiovascular risk while stopping short of recommending B-vitamin therapy for cardiovascular risk reduction, citing the neutral outcome-trial data described above. Some cardiology and biochemistry expert groups have separately described homocysteine as an independent, graded risk marker for cardiovascular disease and mortality in the general population; the exact wording and source of any such consensus statement should be verified against the primary document before it is quoted, since a prior version of this article attributed specific quoted language to a source that could not be confirmed here.
This is a genuine, unresolved tension rather than a settled question: population data say higher is worse, and trial data in people with existing disease say lowering the number does not clearly change hard outcomes. Readers should treat the 7 to 10 µmol/L target as a reasonable, biologically grounded hypothesis used in longevity practice, not as an evidence-based target with outcome-trial support behind it.
Special situations worth flagging
Adults over 60. Homocysteine tends to rise with age due to declining kidney function and reduced B12 absorption from lower gastric acid and intrinsic factor. B12 deficiency is common enough in this age group that it is worth checking directly (with MMA if B12 is borderline) rather than assuming a high homocysteine is purely dietary.
Pregnancy. Homocysteine and folate status have specific, well-established implications in pregnancy (including neural tube defect risk) that are outside the scope of this longevity-medicine page; pregnant or planning-to-conceive readers should discuss folate and homocysteine with their obstetric clinician rather than apply a longevity target intended for a different population.
GLP-1 receptor agonist use. Significant, sustained reduction in food intake and variety, as can happen with semaglutide, tirzepatide, or similar agents, plausibly increases the risk of falling short on B12 and folate. Periodic monitoring is a reasonable precaution in people who have lost a substantial amount of weight on these medications, though this is a clinical inference rather than a finding from a dedicated trial.
Very high results or suspected homocystinuria. Markedly elevated homocysteine, especially at very high multiples of the reference range, can reflect a rare inherited metabolic disorder (homocystinuria) or significant renal or thyroid disease, and warrants clinician-directed evaluation rather than a self-managed supplement trial.
When to seek care rather than self-manage
A homocysteine result on its own is rarely an emergency. Seek medical attention promptly, rather than waiting for a routine follow-up, if a very high result is accompanied by new visual changes, unexplained blood clots, developmental concerns in a child, or a family history of early clotting disorders, since these can point toward homocystinuria or another condition needing specific management. Routine borderline or moderately elevated results are appropriate to discuss at a regular visit.
A decision framework for interpreting and acting on a homocysteine result
| Situation | What the evidence supports | Reasonable next step |
|---|---|---|
| 7 to 10 µmol/L, no other risk factors | Associated with the lower end of cohort risk gradients | Routine monitoring; no intervention indicated on this value alone |
| 10 to 15 µmol/L, "normal" on the lab report, no cardiovascular disease or CKD | Above the longevity target; correctable causes are common at this level | Check B12, MMA (if B12 borderline), folate, TSH, and eGFR before supplementing; retest 8 to 12 weeks after any change |
| 10 to 15 µmol/L, with established cardiovascular disease | Outcome trials in this population did not show reduced cardiovascular events from lowering homocysteine | Treat any documented B-vitamin deficiency on its own merits; do not expect B-vitamin therapy alone to reduce future cardiac events |
| Above roughly 15 to 30 µmol/L | Higher risk category; secondary causes more likely | Evaluate renal function, B12/MMA, thyroid; consider MTHFR discussion with a clinician; supplement under clinician guidance |
| Known MTHFR C677T TT genotype | Reduced conversion of folic acid to its active form | Discuss 5-MTHF versus folic acid with the prescribing clinician rather than self-selecting high-dose folic acid |
| eGFR below 60 mL/min/1.73m² | Kidney clearance impaired; supplementation response often smaller | Involve the treating clinician or nephrology; do not expect full normalization from vitamins alone |
| Very high result or symptoms suggestive of homocystinuria | Possible rare genetic or metabolic disorder | Urgent clinician evaluation, not a supplement trial |
| Result falls below roughly 5 µmol/L on supplementation | Some cohort data have raised questions about very low levels, without establishing causation | Discuss dose adjustment with the prescriber rather than assuming lower is always better |
Monitoring and retesting
- At baseline, fasting plasma homocysteine as part of a broader panel (B12, folate or MMA, TSH, kidney function).
- Roughly 8 to 12 weeks after starting or changing B-vitamin supplementation, to assess response.
- Roughly annually once in the target range, or sooner if kidney function changes, new medications are started, or diet changes substantially.
- A meaningful reduction from baseline is generally expected within 8 to 12 weeks of adequate B-vitamin supplementation; if the value has not moved, recheck B12, folate, TSH, and kidney function before increasing the dose.
How homocysteine fits with other longevity labs
Homocysteine is more informative read alongside other markers than in isolation. Elevated ApoB or LDL particle number alongside elevated homocysteine suggests compounding vascular risk. Elevated hsCRP alongside elevated homocysteine suggests an inflammatory component worth investigating further. Methylmalonic acid (MMA) is a more sensitive marker of functional B12 deficiency than serum B12 alone; a normal MMA with elevated homocysteine points more toward folate deficiency or an MTHFR-related pattern than toward B12 deficiency. Iron-deficiency anemia can also raise homocysteine independently of B-vitamin intake.
Frequently asked questions
What is the optimal range for homocysteine?
What is the normal homocysteine range on a standard lab report?
What causes high homocysteine?
Can homocysteine be lowered with diet alone?
How long does it take for B vitamins to lower homocysteine?
Does the MTHFR gene variant affect homocysteine?
Is homocysteine linked to dementia?
Should homocysteine be tested fasting?
Does testosterone replacement therapy raise homocysteine?
Why didn't lowering homocysteine reduce heart attacks in the major trials?
How often should homocysteine be checked?
A note on sources. This article was rewritten from the prior draft's evidence base. Several specific citations, exact sample sizes, and one direct quotation in the earlier version could not be independently confirmed against the primary literature during this revision and have been removed or converted to general, hedged descriptions rather than left attached to a specific paper. Anyone using this page clinically should verify the underlying cohort studies (including the Hordaland Homocysteine Study, the Framingham Offspring Study, NHANES analyses of homocysteine and mortality, the NORVIT and HOPE-2 trials, and Cochrane reviews of homocysteine-lowering interventions) directly in PubMed or the Cochrane Library before citing specific effect sizes to a patient or in further published material.